GlassScriptPhysician profile
Sharel C Ongchin
NPI 1538324694
$1,026.42
in general payments reported to CMS, 2019-2025
11 companies · $298 in 2025
The $298 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.92 · 2021: $61.17 · 2022: $235 · 2023: $171 · 2024: $240 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $690 · Education: $19.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $690.16 |
| Education | $19.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $325.14 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $182.85 | 2021-2025 | Vabysmo |
| Eyepoint US, INC. | $179.57 | 2021-2022 | |
| Abbvie INC. | $86.34 | 2025 | |
| Alimera Sciences, INC. | $65.41 | 2023-2024 | Iluvien, Yutiq |
| Mallinckrodt Hospital Products INC. | $55.07 | 2023 | Acthar |
| Ani Pharmaceuticals, INC. | $51.28 | 2025 | Purified Cortrophin Gel, Iluvien |
| Apellis Pharmaceuticals, INC. | $23.95 | 2023 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.89 | 2021 | |
| Astellas Pharma US INC | $19.78 | 2024 | Izervay |
| Coherus Oncology, INC. | $17.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharel Ongchin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.